Edition:
India

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

452.52USD
5 Jun 2020
Change (% chg)

$-11.33 (-2.44%)
Prev Close
$463.85
Open
$464.85
Day's High
$464.85
Day's Low
$446.44
Volume
54,491
Avg. Vol
61,072
52-wk High
$496.96
52-wk Low
$286.33

Latest Key Developments (Source: Significant Developments)

Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%
Friday, 22 May 2020 

May 21 (Reuters) - Bio Rad Laboratories Inc ::BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING.  Full Article

Bio-Rad Reports Q1 Non-GAAP Earnings Per Share $1.91
Thursday, 7 May 2020 

May 6 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.91.Q1 EARNINGS PER SHARE $22.72.Q1 SALES ROSE 3.2 PERCENT TO $571.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.57 -- REFINITIV IBES DATA.SEES Q2 SALES DOWN 10 TO 15 PERCENT.WITHDRAWING OUR PREVIOUSLY ISSUED ANNUAL GUIDANCE FOR THIS YEAR.  Full Article

Bio-Rad Acquires Celsee Inc
Thursday, 9 Apr 2020 

April 9 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD ACQUIRES CELSEE, INC., A SINGLE-CELL ANALYSIS SOLUTIONS PROVIDER.BIO RAD LABORATORIES INC - TERMS OF ACQUISITION WERE NOT DISCLOSED.  Full Article

Bio-Rad To Launch Serology Assay To Detect Coronavirus Antibodies
Tuesday, 7 Apr 2020 

April 7 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD ANNOUNCES THE LAUNCH OF A SEROLOGY ASSAY TO DETECT CORONAVIRUS (COVID-19) ANTIBODIES.BIO RAD LABORATORIES INC - PLANS TO OFFER IMMUNOASSAY KIT GLOBALLY.BIO RAD LABORATORIES INC - IN UNITED STATES, CO INTENDS TO USE FDA'S EMERGENCY USE AUTHORIZATION PROCESS TO EXPEDITE U.S. AVAILABILITY.  Full Article

Bio-Rad Reports Q4 Non-Gaap Earnings Per Share $2.32
Friday, 14 Feb 2020 

Feb 13 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $18.31.Q4 NON-GAAP EARNINGS PER SHARE $2.32.Q4 SALES $624.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $641.9 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $2.45 -- REFINITIV IBES DATA.QTRLY NET SALES WERE $624.4 MILLION , AN INCREASE OF 1.2 PERCENT COMPARED TO $616.8 MILLION REPORTED FOR FOURTH QUARTER OF 2018.BIO RAD LABORATORIES - CYBERATTACK ON CO'S NETWORK ON DEC 5, 2019 DID HAVE AN IMPACT ON SALES & OPERATIONS DURING DEC 2019.FOR THE FULL YEAR 2020, CO ANTICIPATES CURRENCY-NEUTRAL REVENUE GROWTH OF ABOUT 4.5 TO 5.25 PERCENT.SEES 2020 CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 4.5 TO 5.25 PERCENT.  Full Article

Bio Rad Says It Initiated Strategy-Driven Restructuring Plan On November 21
Tuesday, 26 Nov 2019 

Nov 25 (Reuters) - Bio Rad Laboratories Inc ::BIO RAD LABORATORIES INC SAYS ON NOVEMBER 21, CO INITIATED STRATEGY-DRIVEN RESTRUCTURING PLAN - SEC FILING.BIO RAD LABORATORIES - RESTRUCTURING PLAN INCLUDES WORKFORCE REDUCTION, PRIMARILY IN EUROPE, WHICH CO ANTICIPATES TO BE SUBSTANTIALLY COMPLETED BY END OF Q2 OF 2020.BIO RAD LABORATORIES - ESTIMATES WILL INCUR ABOUT $27 MILLION IN TOTAL COST AS RESULT OF RESTRUCTURING.BIO RAD LABORATORIES SAYS ANTICIPATES THAT IT WILL RECORD MAJORITY OF RESTRUCTURING CHARGES IN Q4 OF 2019.BIO RAD LABORATORIES - EXPECTS SIGNIFICANT PORTION OF NET SAVINGS RESULTING FROM RESTRUCTURING PLAN WILL BE REPURPOSED IN ALIGNMENT WITH CO'S PORTFOLIO STRATEGY.  Full Article

10X Genomics - On November 20, Court Ruled That Co’S Gem Microfluidic Chips Infringed The German Utility Model
Monday, 25 Nov 2019 

Nov 25 (Reuters) - 10X Genomics Inc ::10X GENOMICS INC - ON NOVEMBER 20, COURT RULED THAT CO’S GEM MICROFLUIDIC CHIPS INFRINGED THE GERMAN UTILITY MODEL.10X GENOMICS -COURT ISSUED INJUNCTION PROHIBITING SALE OF GEM MICROFLUIDIC CHIPS, CHROMIUM INSTRUMENTS, ACCESSORIES USED WITH SUCH SYSTEMS IN GERMANY.10X GENOMICS -COURT ISSUED INJUNCTION PROHIBITING IMPORTATION OF GEM MICROFLUIDIC CHIPS, CHROMIUM INSTRUMENTS, ACCESSORIES INTO GERMANY.10X GENOMICS - COURT FOUND THAT CO IS OBLIGATED TO COMPENSATE BIO-RAD FOR UNSPECIFIED DAMAGES.10X GENOMICS - COURT FOUND CO IS REQUIRED TO RECALL GEM MICROFLUIDIC CHIPS, CHROMIUM INSTRUMENTS, ACCESSORIES FROM DISTRIBUTION CHANNELS IN GERMANY.10X GENOMICS - COURT’S RULING DID NOT ADDRESS CO’S NEXT GEM PRODUCTS, WHICH WERE NOT ACCUSED IN THE ACTION.10X GENOMICS INC - COURT ALSO FOUND THAT CO HAS TO BEAR STATUTORY COSTS OF LEGAL DISPUTE IN MINIMUM AMOUNT OF AT LEAST 61,000 EUROS.  Full Article

Bio Rad Laboratories Posts Q3 Adj EPS Of $1.61
Friday, 1 Nov 2019 

Oct 31 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD REPORTS THIRD-QUARTER 2019 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $1.61.Q3 SALES ROSE 2.8 PERCENT TO $560.6 MILLION.Q3 LOSS PER SHARE $8.68.Q3 EARNINGS PER SHARE VIEW $1.41, REVENUE VIEW $565.0 MILLION -- REFINITIV IBES DATA.  Full Article

Bio-Rad Files New Lawsuit Against 10X Genomics For Patent Infringement
Thursday, 12 Sep 2019 

Sept 11 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD FILES NEW LAWSUIT AGAINST 10X GENOMICS FOR PATENT INFRINGEMENT.BIO RAD LABORATORIES INC - IS SEEKING ALL AVAILABLE REMEDIES AGAINST 10X GENOMICS, INCLUDING DAMAGES AND INJUNCTIVE RELIEF.BIO RAD - IN LAWSUIT, CO ASSERTS 10X GENOMICS INFRINGES PATENT WHICH COVERS TECHNIQUES FOR DETECTING ENZYMATIC REACTIONS IN MICROFLUIDIC DROPLETS.  Full Article

Bio-Rad Posts Q2 EPS Of $19.86
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Bio Rad Laboratories Inc ::BIO-RAD REPORTS SECOND-QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $1.57.Q2 EARNINGS PER SHARE $19.86.Q2 SALES $572.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $566.2 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.34 -- REFINITIV IBES DATA.FOR FY 2019, COMPANY CONTINUES TO ANTICIPATE CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 4.0 TO 4.5%.  Full Article

BRIEF-Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%

* BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING Source text: (https://bit.ly/3glQfJ0) Further company coverage: